Abivax (ABVX) Cash from Discontinued Operations (2025 - 2026)

Abivax (ABVX) posted quarterly Cash from Discontinued Operations of 59144899.5 for Q1 2026, down 68.96% year-over-year from 190563599.23 in Q1 2025, and down 68.96% quarter-over-quarter from 35004610.38 in Q1 2025.

Abivax (ABVX) Cash from Discontinued Operations (2025 - 2026) Analysis & Trends

Abivax's Cash from Discontinued Operations history runs 2 years deep, the most recent figure standing at 59144899.5 for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 7.90 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Abivax 9.39 Bn 9.39 Bn - -53.32 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -59.14 Mn
Mar 31, 2026 -59.14 Mn
Mar 31, 2025 -35.00 Mn
Mar 31, 2025 -35.00 Mn